Anti-TNF-alpha therapy for acute rejection in intestinal transplantation.

Transplant Proc

Department of General and Transplantation Surgery, Charité, Campus Virchow Clinic, Berlin, Germany.

Published: April 2005

AI Article Synopsis

Article Abstract

Introduction: We present our experience with infliximab rescue therapy for steroid- and OKT3-resistant rejection after intestinal transplantation (ITx).

Methods: Twelve ITx and one multivisceral transplant recipients were immunosuppressed with tacrolimus, rapamycin, daclizumab, steroids (n = 10) or tacrolimus, campath, and steroids (n = 3).

Results: In two patients, severe acute rejection did not resolve despite steroid bolus therapy plus 5 to 10 days of OKT3 treatment. Signs of moderate rejection persisted in the distal portions of the grafts. Treatment with infliximab, a chimeric anti-TNF-alpha antibody (four infusions of 3 mg/kg body weight), induced a complete remission of histological and clinical signs of rejection. Two further patients with steroid-resistant rejection received two courses of infliximab (3 mg/kg body weight) as antirejection therapy. All rejection episodes resolved completely.

Conclusions: Infliximab effectively treats steroid and OKT3 resistant acute rejection episodes of intestinal transplantations.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2004.09.023DOI Listing

Publication Analysis

Top Keywords

acute rejection
12
rejection
8
rejection intestinal
8
intestinal transplantation
8
mg/kg body
8
body weight
8
rejection episodes
8
anti-tnf-alpha therapy
4
therapy acute
4
transplantation introduction
4

Similar Publications

Background: Intestinal transplantation (ITx) represents the only curative option for patients with irreversible intestinal failure. Nevertheless, its rejection rate surpasses that of other solid organ transplants due to the heightened immunological load of the gut. Regulatory T-cells (Tregs) are key players in the induction and maintenance of peripheral tolerance, suggesting their potential involvement in modulating host vs.

View Article and Find Full Text PDF

Background: Acute rejection (AR) is one of the significant factors contributing to poor prognosis in patients following kidney transplantation. Neutrophils are the main cause of early host-induced tissue injury. This paper intends to investigate the possible mechanisms of neutrophil involvement in acute rejection in renal transplantation.

View Article and Find Full Text PDF

A novel Sai-based antioxidant agent attenuates antibody-mediated rejection in allogeneic rat kidney transplantation.

Am J Transplant

January 2025

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan; Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Electronic address:

Antibody-mediated rejection (ABMR) remains a leading cause of graft loss during kidney transplantation. Ischemia reperfusion injury (IRI) has been reported to promote T-cell proliferation, leading to B-cell activation and subsequent production of donor-specific antibodies (DSA), which target antigens on the vascular endothelium. We hypothesize that a novel therapeutic strategy targeting highly toxic reactive oxygen species could mitigate oxidative stress and immune responses associated with IRI.

View Article and Find Full Text PDF

[Nephrology : what's new in 2024 (II)].

Rev Med Suisse

January 2025

Service de néphrologie, Département de médecine, Hôpitaux universitaires de Genève, Genève 14.

Certain molecules, such as GLP-1 agonists and endothelin antagonists, possess nephroprotective properties. When treating IgA nephropathy, endothelin antagonists and sibeprenlimab have shown effectiveness in slowing the progression of chronic kidney isease. Additionally, the infusion of amino acids can reduce the incidence of mild acute kidney injury following cardiac surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!